Abstract
Background: Gynaecological malignancies including cervical, ovarian, endometrial, and vulvar cancers, and gestational trophoblastic disease represent a significant global health burden. Accurate staging, early detection of recurrence, and timely assessment of treatment response are critical for improving patient outcomes. Conventional imaging modalities such as Ultrasonography (USG), Computed Tomography (CT), and Magnetic Resonance Imaging (MRI) primarily provide anatomical information and may have limitations in differentiating viable tumor tissue from post-treatment changes. Positron Emission Tomography (PET), particularly 18F-fluorodeoxyglucose (18F-FDG) PET/CT, hybrid imaging modality offers for functional as well as anatomical information and has emerged as an important tool in gynaecologic oncology. Objective: To review the principles, clinical applications, comparative performance, and emerging advances of PET imaging in gynaecological disorders. Materials and Methods: A comprehensive narrative review of literature published between 2005 and 2025 was conducted using major electronic databases including PubMed, Scopus, Embase, and Google Scholar. Studies evaluating PET, PET/CT, and PET/MRI in gynaecological malignancies were analyzed, with emphasis on diagnostic accuracy, staging performance, treatment response assessment, prognostic value, and comparison with conventional imaging modalities. Results: PET/CT demonstrated superior specificity for detecting pelvic and para-aortic lymph node metastases in cervical and endometrial cancers compared to CT and MRI. In ovarian cancer, PET/CT showed greatest utility in detecting recurrent disease, particularly in patients with rising CA-125 levels and inconclusive conventional imaging. PET imaging was effective in assessing treatment response and identifying recurrence across malignancies, often detecting metabolic changes prior to anatomical alterations. Quantitative parameters such as Standardized Uptake Value (SUV) provided prognostic information. Novel radio tracer such as 68Ga-FAPI show promising potential in improving tumor characterization. However, limitations include reduced sensitivity for small lesions, false-positive uptake in inflammatory conditions and higher cost. Conclusion: PET imaging, particularly FDG PET/CT, serves as a valuable complementary modality in the management of gynecological malignancies. By integrating metabolic and anatomical information, it enhances staging accuracy, guides treatment planning, and improves detection of recurrence. With ongoing technological advancements, PET-CT based molecular imaging is expected to play an increasingly central role in precision gynecologic oncology.